Bhopal (Madhya Pradesh): AIIMS Bhopal is set to expand its health infrastructure on a large scale this year, which will help patients get advanced treatment within the state. According to AIIMS ...

Data on epcoritamab with rituximab and lenalidomide, results on a novel oral CELMoD agent, and outcomes from late-line CAR T-cell therapy are among highlights in follicular lymphoma (FL) presented at ...

Clinical trial results showed an objective response rate of 75% (95% CI, 64-83), with 59% of patients having a complete response and 16% having a partial response. The Food and Drug Administration ...

– Approval supported by data demonstrating compelling complete response rate in third-line or later follicular lymphoma, which typically becomes harder to treat after each relapse – Genentech, a ...

(RTTNews) - Incyte Corp. (INCY) announced on Thursday that the European Commission has approved Minjuvi in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed ...

Katelyn is a writer with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content ...

Please provide your email address to receive an email when new articles are posted on . The addition of epcoritamab to rituximab and lenalidomide improved PFS and response rate. The regimen is a ...

Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R 2) resulted in statistically significant and clinically meaningful reduction in the risk of disease ...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced primary data from the pivotal Phase 3 EPCORE ® FL-1 study evaluating fixed duration EPKINLY ® (epcoritamab-bysp) in ...

Researchers from Memorial Sloan Kettering Cancer Center (MSK) announced today that the latest results from that follicular lymphoma clinical trial have shown the three-drug combination — rituximab ...

Andrew Zelenetz, MD, PhD, addresses the potential for CD19 antigen loss, the lack of robust data, and the influence of newer, highly efficacious combination therapies on the sequencing decisions in ...